Piomic Medical Wins EPUAP 2024 Most Innovative Product Award
Award highlights promising potential of COMS® therapy for severe pressure ulcers, with off-label data showing “clinically significant rates of wound area reduction and wound closure“1.
Written by
Published on
Zurich, Switzerland – 04 October 2024 – Piomic Medical, a leader in innovative wound care solutions, is proud to announce that the COMS® One Therapy System has been awarded the Most Innovative Product Award at the European Pressure Ulcer Advisory Panel (EPUAP) 2024 conference. This prestigious award highlights the significant potential of COMS® therapy in advancing the treatment of severe pressure ulcers, a leading cost driver in wound care with very limited treatment options.
Severe stage IV pressure ulcers account for only around 13% of pressure ulcers but are responsible for nearly 59% of the total wound care costs associated with pressure ulcers.2 These ulcers are notoriously difficult to treat and pose a significant burden on healthcare systems. The COMS® One Therapy System, while not yet cleared for treating pressure ulcers, has shown promising initial data in severe cases. An abstract presented at EPUAP 2024 demonstrated an average Wound Surface Area Reduction (WSAR) of 77% and a 42% complete closure rate in stage IV ulcers, which are typically difficult to treat and represent a substantial healthcare cost burden.1
Martin Walti, Chief Operations Officer at Piomic, commented: “We are honored to receive this recognition from EPUAP. It underscores the potential impact of our COMS® therapy in revolutionizing the treatment of severe pressure ulcers, where few options exist today. This award inspires us to continue innovating and pushing forward to bring this solution to patients globally.”
The award comes at a crucial time as Piomic Medical continues to validate the efficacy of COMS® therapy through clinical investigations. The Medicare-approved FDA IDE trial MAVERICKS is currently evaluating the potential beneficial effects of COMS® treatment in patients suffering from therapy-refractory diabetic foot ulcers. Additionally, the NAZARE trial in Europe will investigate Concurrent Optical and Magnetic Stimulation (COMS) for the treatment of patients with chronic ulcers of vascular origin in a real-world setting. These prospective, randomized, controlled clinical trials will help provide a strong foundation for future regulatory approvals and commercialization strategies across key markets.
About Piomic Medical
Piomic develops cutting-edge medical devices designed to treat hard-to-heal wounds based on its proprietary COMS® therapy, which utilizes concurrent optical and magnetic stimulation. COMS® therapy is intuitive, fits within existing clinical workflows, and offers a promising solution for healthcare professionals dealing with ulcers that do not respond to standard care. With its innovative approach, Piomic aims to reduce healthcare costs while improving patient outcomes.
Important Regulatory Disclaimers
The COMS® therapy system has not been cleared or approved by regulatory authorities for the treatment of pressure ulcers. Any statements regarding the safety and effectiveness of the system for this indication are not applicable, as regulatory clearance or approval has not yet been obtained.
Literature References
1. Sarmiento K, Casela AM, Gamboa JF, Siton VAG, Granada MJ, Ratilla J. A first-in-human evaluation of concurrent optical and magnetic stimulation in severe hard-to-heal pressure ulcers.
2. Padula WV, Delarmente BA. The national cost of hospital-acquired pressure injuries in the United States. International Wound Journal. 2019;16(3):634-640. doi:10.1111/iwj.13071